Compare Amgen, Inc. (AMGN) vs Devon Energy Corp (DVN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs Devon Energy Corp — how do they compare? Amgen, Inc. trades at $362.14 (market cap $196.12B), while Devon Energy Corp trades at $42.93 (market cap $48.71B). The key difference: Amgen, Inc. is far larger — about 4× Devon Energy Corp's market cap, and Amgen, Inc. pays the higher dividend (2.77%). Which is the better fit depends on your goals.
| AMGN | DVN | |
|---|---|---|
Market Cap | $196.12B | $48.71B |
Sector | Health | Energy |
52-Week High | $388.16 | $52.07 |
52-Week Low | $271.18 | $31.74 |
Enterprise Value | $241.41B | $55.49B |
Dividend Yield | 2.77% | 2.46% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
Devon Energy (DVN) trades at $42.23, up 0.5% with neutral technical signals. The company shows strong fundamentals with a P/E of 11.76 and ROE of 15.13%, though revenue declined from $19.2B in 2022 to $17.2B in 2025. Recent Q1 2026 earnings missed expectations, but Q3 and Q4 2025 beat estimates. Positive sentiment includes 71% analyst buy ratings and a $60.55 consensus target, while activist investor TOMS Capital pushes for asset sales or company sale (Reuters, 2026-06-17).
DVN offers value with discounted valuation and $1B synergy potential from the Coterra merger, but faces oil price volatility and execution risks. The stock trades 30% below analyst targets, presenting upside if operational targets are met, though debt levels and margin compression require monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Devon Energy Corp
Devon Energy, based in Oklahoma City, is one of the largest independent exploration and production companies in North America. The firm's asset base is spread throughout onshore North America and includes exposure to the Delaware, STACK, Eagle Ford, Powder River Basin, and Bakken plays. At year-end 2021, Devon's proved reserves totaled 1.6 billion barrels of oil equivalent, and net production that year was 572 thousand boe/d, of which oil and natural gas liquids made up 74% of production, with natural gas accounting for the remainder.
Read more on DVN →
